N-acetylcysteine for radiocontrast-induced nephropathy: Potential role in the emergency department?

Canadian Journal of Emergency Medicine

Volumn 6, Issue 4, 2004, Pages 253-258

  Chong, Elaine ^a   Zed, Peter J ^b,c,d  

^a Clinical Services   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c Faculty of Pharmaceutical Sciences   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Emergency; N acetylcysteine; Nephropathy; Radiocontrast; Renal failure

Indexed keywords

ACETYLCYSTEINE; CONTRAST MEDIUM;

CONSTIPATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; EMBASE; EMERGENCY WARD; FLUSHING; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYDRATION; KIDNEY DISEASE; LUNG EDEMA; MEDLINE; NAUSEA; PRURITUS; RADIOCONTRAST INDUCED NEPHROPATHY; REVIEW; STOMACH DISEASE; THORAX PAIN;

EID: 18244393988     PISSN: 14818035     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1481803500009210     Document Type: Review

References (20)

1. Nissenson AR. Acute renal failure: definition and pathogenesis. Kidney Int 1998;53:S7-10.
2. Pruchnicki MC, Dasta JF. Acute renal failure in hospitalized patients: Part I. Ann Pharmacother 2002;36:1261-7.
3. Pruchnicki MC, Dasta JF. Acute renal failure in hospitalized patients: Part II. Ann Pharmacother 2002;36:1430-42.
4. Asif A, Preston RA, Roth D. Radiocontrast-induced nephropathy. Am J Ther 2003;10:137-47.
5. Gerlach AT, Pickworth KK. Contrast medium-induced nephrotoxicity: pathophysiology and prevention. Pharmacotherapy 2000;20:540-8.
6. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationships to mortality. Am J Med 1997;103:368-75.
7. Waybill MM, Waybill PN. Contrast media-induced nephrotoxicity: identification of patients at risk and algorithms for prevention. J Vasc Interv Radiol 2001;12:3-9.
8. Safirstein R, Andrade L, Vieira JM. Acetylcysteine and nephrotoxic effects of radiographic contrast agents - a new use for an old drug. N Engl J Med 2000;343:210-2.
9. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-4.
10. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 2002;89:356-8.
11. Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 2002;40:1383-8.
12. Kay J, Chow WH, Chan TM, Lo SK, Kwok ON, Yip A, et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA 2003;289:553-8.
13. Baker CSR, Wragg A, Kumar S, De Palma R, Baker LRI, Knight CJ. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID Study. J Am Coll Cardiol 2003;41:2114-8.
14. Briguori C, Manganelli F, Scarpato P, Elia PP, Golia B, Riviezzo G, et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2002;40:298-303.
15. Allaqaband S, Tumuluri R, Malik AM, Gupta A, Volkert P, Shale v Y, et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Cathet Cardiovasc Intervent 2002;57:279-83.
16. Durham JD, Caputo C, Dokko J, Zaharakis T, Pahlavan M, Keltz J, et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 2002;62:2202-7.
17. Oldemeyer JB, Biddle WP, Wurdeman RL, Mooss AN, Cichowski E, Hilleman DE. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. Am Heart J 2003;146:e23.
18. Holdiness MR. Clinical pharmacokinetics of N-acetylcysteine. Clin Pharmacokinet 1991;20:123-34.
19. Birck R, Krzossok S, Markowetz F, Schnulle P, van der Woude FJ, Braun C. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 2003;362:598-603.
20. Borgstrom L, Kagedal B. Dose dependent pharmacokinetics of N-acetylcysteine after oral dosing to man. Biopharm Drug Dispos 1990;11:131-6.